[1]Herman JG, merlo A, Mao Li, et al.Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNAmethylation in all common human cancer[J].Cancer Res, 1995, 55 (20) :4525-4530.
|
[2]Rein T, Depamphillis ML, Zorbas H, et al.Identifying5-methylcytosine and related modification in DNA genes[J].Nucleic Acids Res, 1995, 55 (20) :4525-4530.
|
[3]Kamiyama H, Noda H, Takata O, et al.Promoter hypermethylation of tumor-related genes in peritoneal lavage and theprognosis of patients with colorectal cancer[J].J Surg Oncol, 2009, 100 (1) :69-74.
|
[4]Powell SM, Zilz N, Bryan TM, et al.APC gene mutation occurearly during colorectal tumorigenesis[J].Nature, 1992, 359 (6392) :235-237.
|
[5]Homma MK, Li D, Krebs EG, et al.Association and regulationof casein kinase 2 activity by adenomatous polyposis coliprotein[J].Proc Natl Acad Sci U S A, 2002, 99 (9) :5959-5964.
|
[6]Yutaka S, Chi WW, Yutaka K, et al.Epigenetic-Genetic Interactionsin the APC/WNT, RAS/RAF, and P53 Pathways in ColorectalCarcinoma[J].Clin Cancer Res 2008, 14 (9) :2560-2569.
|
[7]Kumar K, Brin H, Giardiello F, et al.Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadiccolorectal cancer in African Americans[J].Clin Cancer Res, 2009, 15 (4) :1155-1161.
|
[8]Tang M, Torres-Lanzas J, Lopez-Rios F, et al.Wnt signalingpromoter hypermethylation distinguishes lung primaryadenocarcinomas from colorectal metastasis to the lung[J].Int J Cancer, 2006, 119 (11) :2603-2606.
|
[9]吴龙, 钱叶本, 朱立新, 等.肝细胞癌中SFRP1和APC基因启动子甲基化与其mRNA的表达[J].中国普通外科杂志, 2008, 17 (1) :29-33.
|
[10]Kiran M, Chawla YK, Kaur J, et al.Methylation profiling oftumor suppressor genes and oncogenes in hepatitis virus-related hepatocellular carcinoma in northern India[J].CancerGenet Cytogenet, 2009, 195 (2) :112-119.
|
[11]Lee HC, Kim M, Wands JR, et al.Wnt/Frizzled signaling inhepatocellular carcinoma[J].Front Biosci, 2006, 11:1901-1915.
|
[12]Colnot S, Decaens T, Niwa Kawakita M, et al.Liver-targetedDisruption of Apc in Mice Activates Beta-catenin Signalingand Leads to Hepatocellular Carcinomas[J].Proc Natl AcadSci U S A, 2004, 101 (49) :17216-17221.
|
[13]Ksiaa F, Ziadi S, Amara K, et al.Biological significance of promoterhypermethylation of tumor related genes in patients with gastriccarcinoma[J].Clin Chim Acta, 2009, 404 (2) :128-133.
|
[14]Lee SH, Kang HJ, Shin DH, et al.Expression of beta-cateninand its mechanism of delocalization in intestinal-typeearly gastric cancer based on mucin expression[J].HistolHistopathol, 2009, 24 (7) :831-838.
|
[15]Esteller M, Sparks A, Toyota M, et al.Analysis of adenom-atous polyposis coli promoter hypermethylation in humancancer[J].Cancer Res, 2000, 60 (16) :4366-4371.
|
[16]Clement G, Braunschweig R, Pasquier N, et al.Methy-lation of APC, TIMP3, and TERT:a new predictive marker todistinguish Barrett's oesophagus patients at risk for malignanttransformation[J].J Pathol, 2006, 208 (1) :100-107.
|
[17]Brock MV, Gou M, Akiyama Y, et al.Prognostic importance ofpromoter hypermethylation of multiple genes in esophagealadenocarcinoma[J].Clin Cancer Res, 2003, 9 (8) :2912-2919.
|
[18]丁振, 钱叶本, 熊奇如, 等.肝细胞癌中WIF-1基因启动子甲基化状态及mRNA表达的研究[J].肝胆外科杂志, 2008, 16 (4) :304-307.
|
[19]张影, 张福奎, 王宝恩.经典Wnt信号通路与肝脏病的研究进展[J].世界华人消化杂志, 2008, 16 (9) :975-981.
|
[20]程勤, 金洁, 于彬, 等.肝癌细胞中WIF-1的甲基化状态分析[J].复旦学报, 2007, 34 (6) :843-847.
|
[21]郭艳丽, 郭炜, 靳国梁, 等.贲门腺癌WIF-1基因启动子区甲基化状态的检测及临床意义[J].第三军医大学学报, 2009, 32 (21) :2094-2097.
|
[22]Taniguchi H, Yamamoto H, Hirata T, et al.Freque-nt epigeneticinactivation of Wnt inhibitory factor-1 in human gastrointestinalcancers[J].Oncogene, 2005, 11 (53) :7946-7952.
|
[23]Lee BB, Lee EJ, Jung EH, et al.Aberrant methylation ofAPC, MGMT, RASSF2A, and Wif-1 genes in plasma as abiomarker for early detection of colorectal cancer[J].ClinCancer Res, 2009, 15 (19) :6185-6191.
|
[24]Taniguchi H, Yamaoto H, Hirata T, et al.Frequent epigeneticinactivation of Wnt inhibitory factor-1 in human gastrointestinalcancers[J].Oncogene, 2005, 11 (53) :7946-7952.
|
[25]Hu L, Chen G, Yu HP, et al.Clinicopathological significanceof RASSF1A reduced expression and hypermethylation inhepatocellular carcinoma[J].Hepatol Int, 2010, 4 (1) :423-432.
|
[26]周晓俊, 薛万江, 秦磊, 等.原发性肝癌中RASSF1A基因表达失活及其临床意义[J].江苏医药, 2007, 33 (1) :24-27.
|
[27]Chan KC, Lai PB, Mok TS, et al.Quantitative analysis ofcirculating methylated DNA as a biom arker for hepatocellularcarcinoma[J].Clin Chem, 2008, 54 (9) :1528-1536.
|
[28]刘培, 姜相君, 葛银林, 等.RASSF1A基因启动子区甲基化在胃癌组织中的检测[J].世界华人消化杂志, 2009, 17 (30) :3144-3147.
|
[29]蒋鹏程, 马圭, 孟鑫, 等.RASSF1A在胃癌中的甲基化检测及表达[J].现代肿瘤医学, 2009, 17 (6) :1115-1118.
|
[30]Tamotsu K, Francesco T, Sai Y, et al.Promoter Hype-rmethylation of RASSF1A in Esophageal Squamous CellCarcinoma[J].Clin Cancer Res, 2003, 9 (4) :1441-1445.
|
[31]Gonzalo V, Lozano JJ, Balaguer F, et al.Aberrant genepromoter methylation associated with sporadic multiplecolorectal cancer[J].PLoS One, 2010, 5 (1) :e8777.
|
[32]Sakamoto LHT, DE Camargo B, Cajaiba M, et al.MT1Ghypermethylation:a potential prognostic marker forhepatoblastoma[J].Pediatr Res, 2010, 67 (4) :387-393.
|
[33]Jin Z, Mori Y, Hamilton JP, et al.Hypermethylation of thesomatostatin promoter is a common, early event in humanesophageal carcinogenesis[J].Cancer, 2008, 112:43-49.
|
[34]董科, 李波, 覃扬, 等.5-氮杂胞苷抑制肝癌细胞恶性表型和逆转甲基化状态的作用及机制[J].世界华人消化杂志, 2008, 16 (17) :1842-1848.
|
[1] | Hou YiHui, Liu TengFei, Zhao XiaoQing, Zhang LiaoYun. Effect of different direct-acting antivirals on the clinical outcome of genotype 1b chronic hepatitis C and compensated hepatitis C cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 84-87. doi: 10.3969/j.issn.1001-5256.2020.01.019 |
[2] | Zhang JieBing, Guo HongHua. Research advances in hepatitis B cirrhosis with renal injury and the application of antiviral drugs[J]. Journal of Clinical Hepatology, 2019, 35(1): 191-196. doi: 10.3969/j.issn.1001-5256.2019.01.042 |
[3] | Zhang Xi, Li YongGuo. Current status of the application of direct-acting antiviral agents in treatment of chronic hepatitis C and existing problems[J]. Journal of Clinical Hepatology, 2018, 34(4): 853-857. doi: 10.3969/j.issn.1001-5256.2018.04.034 |
[4] | Ren Shan, Chen XinYue. Current research on hepatitis C virus resistance to direct-acting antiviral agents[J]. Journal of Clinical Hepatology, 2015, 31(11): 1807-1812. doi: 10.3969/j.issn.1001-5256.2015.11.010 |
[5] | Yang YanLin, Xiao Ping, Gao Peng, Wang LiMing, Wei XiSheng, He Qiang, Zhou Ping. Distribution of HBV genotypes and YMDD mutations in E antigen-positive patients[J]. Journal of Clinical Hepatology, 2012, 28(6): 428-430. |
[6] | Zhang YanMei, Ding XiaoHui. Anti-viral therapy in adult patients with acute hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(12): 1327-1330+1344. |
[7] | Guo XinHui, Yan Yan, Li Zhuo, Yin JiMing. Fluorescent reverse transcription-PCR assay for determination of hepatitis C virus genotypes[J]. Journal of Clinical Hepatology, 2011, 27(1): 65-67. |
[8] | Cheng Ling, Hong GuoHu, Guo Yan, Mao Qing. Prediction of HLA-DRB1*0311/0401 in recognizing epitopes of HCV Core protein of different genotypes[J]. Journal of Clinical Hepatology, 2011, 27(1): 61-64. |
[9] | Liu JinPing, Liu YouDe, Guo YanMei, Yang ShaoPing, Lin Qing, Lin Ling. Clinical characteristics and distribution of hepatitis B virus genotypes in CHB patients in Yantai area[J]. Journal of Clinical Hepatology, 2011, 27(12): 1288-1290. |
[10] | Qin Hua, Wu XiaoQing. Distribution and clinical significance of HBV genotypes in Lanzhou district[J]. Journal of Clinical Hepatology, 2010, 26(3): 295-296. |
[11] | Zhang WenJie, Liu LiJun, Du ShaoCai, Li ChaoXia, Lu QingYun, Yang ShaoHua. The prevalence of hepatitis C virus genotype in Lanzhou area[J]. Journal of Clinical Hepatology, 2010, 26(3): 290-291+294. |
[12] | Wang GuoQiang, Niu JuXia. The HBx protein mutation among different HBV genotypes[J]. Journal of Clinical Hepatology, 2010, 26(4): 392-394. |
[13] | Chen Yan, Tian DeYing, Xia NingShao. Epidemiology and the genotypes of HEV isolated from patients with hepatitis E in Wuhan[J]. Journal of Clinical Hepatology, 2006, 22(1): 36-38. |
[14] | Xiao Yang, Hu CaoHan, Zhou YueJin, Xie QingRong, Zhu BingXing, Hu Xia, Wang KaiJian, Zhang WenJing. Effect of hepatitis B virus genotypes on response to interferon α2b in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2006, 22(2): 105-106. |
[15] | Liu ChengYong, Hou YuanPei, Qian XiuMei, Sun Qing, Song Li. Distribution of hepatitis B virus genotype in Xuzhou and its clinical significance[J]. Journal of Clinical Hepatology, 2005, 21(3): 151-152. |
[16] | Li TingMing, Zhu YouFu, He HaiTang, Mao QianGuo, Wu AiHua, Liang YuFang, Luo KangXian. The relation between chinese hepatitis B virus genotype B C and efficacy of interferon-α.[J]. Journal of Clinical Hepatology, 2005, 21(1): 16-18. |
[18] | Xu ZhengJu, Yang Hong, Zhang QiHua, Chen XianLi, Li ShuQing, Wang ChongGuo. Study on the relationship between hepatitis B virus genotypes and effect of lamivudine therapy.[J]. Journal of Clinical Hepatology, 2005, 21(3): 157-159. |
[19] | Jiao Jian, Wang JiangBin. Distribution of HCV genotypes and its clinical features in patients coinfected with HCV and HBV[J]. Journal of Clinical Hepatology, 2004, 20(2): 75-76. |
[20] | Yao Gang, Zhang Lian, Bao LiHua. HBV genotypes and efficacy of interferon-α on patients with chronic hepatitis B.[J]. Journal of Clinical Hepatology, 2002, 18(5): 273-274. |